Welcome to our dedicated page for Vor Biopharma SEC filings (Ticker: VOR), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The Vor Biopharma Inc. (Vor Bio) SEC filings page on Stock Titan provides streamlined access to the company’s regulatory disclosures as filed with the U.S. Securities and Exchange Commission. As a Nasdaq Global Select Market issuer trading under the symbol VOR, Vor Bio reports on its clinical-stage biotechnology business focused on telitacicept, a dual BAFF/APRIL fusion protein being developed for serious autoimmune diseases.
Through this page, readers can review current and historical filings such as Forms 10‑K and 10‑Q for detailed discussions of risk factors, financial condition, and the status of telitacicept clinical programs, along with Form 8‑K reports describing material events. Recent 8‑K filings have covered topics including underwritten public offerings of common stock, a private placement with institutional investors, a reverse stock split, changes to equity incentive plans, and governance updates involving Board and executive appointments.
Vor Bio also uses 8‑K filings to furnish investor presentations and clinical data updates, for example webcasts and slide decks discussing late-breaking Phase 3 results for telitacicept in Sjögren’s disease and IgA nephropathy, as well as global development plans in generalized myasthenia gravis. Other filings, such as proxy statements (DEF 14A), describe stockholder proposals related to equity plans, warrant issuances, and capital structure changes.
On Stock Titan, these documents are complemented by AI-powered summaries that highlight key points from lengthy filings, helping users quickly understand how new financings, clinical milestones, or corporate actions may affect Vor Bio’s capital structure and development strategy. Investors can also locate information related to registered offerings on Form S‑3, at‑the‑market sales programs, and other registration statements referenced in the company’s 8‑K disclosures. This page is designed to make it easier to follow the regulatory record behind VOR, from financial reporting to telitacicept’s progress through late-stage development.
Vor Biopharma Inc. is registering up to 13,876,032 shares of common stock for resale on behalf of investors from a December 18, 2025 private placement. These shares were sold at $10.81 per share for gross proceeds of $150 million, which the company has already received.
The selling stockholders may dispose of their shares over time in public or private transactions, and Vor Biopharma will not receive any proceeds from these resales. Vor is a clinical-stage biopharma company developing telitacicept for autoimmune diseases, including a global Phase 3 trial in generalized myasthenia gravis.
Vor Biopharma Inc. furnished an update on its financial position and upcoming investor outreach. For the fiscal year ended December 31, 2025, the company estimates that its cash, cash equivalents and short-term investments totaled approximately $450 million. This figure is preliminary, unaudited and may change once full year-end financial statements are completed and reviewed by the company’s independent registered public accounting firm.
Vor also highlighted its participation in the 44th Annual J.P. Morgan Healthcare Conference in San Francisco, including a corporate presentation scheduled for January 13, 2026, from 10:30 a.m. to 11:10 a.m. PT at The Westin St. Francis, Georgian Room. The related investor presentation is available on the company’s website and attached as Exhibit 99.1, and the information is being furnished rather than filed under securities law provisions.
Vor Biopharma Inc. entered into a private securities purchase agreement with institutional investors to sell 13,876,032 shares of common stock at $10.81 per share, raising gross proceeds of about $150.0 million. The company plans to use the net proceeds to advance its clinical pipeline and for general corporate purposes.
Vor also agreed to a registration rights agreement requiring it to file a resale registration statement for these shares on Form S-3 and to seek effectiveness within set deadlines, with liquidated damages owed to investors if deadlines are missed. Separately, director Sarah Reed resigned, and the board appointed Andrew Levin as an independent Class II director and Wouter Joustra as an independent Class III director, with both receiving the standard non-employee director cash and equity compensation and entering into the company’s standard indemnification agreements.
Vor Biopharma Inc. reported an insider equity update involving its officer serving as CFO. On December 5, 2025, the company’s compensation committee approved the cancellation of 694,137 restricted stock units, leaving the reporting person with no directly held common stock after the transaction.
On the same date, the CFO acquired an employee stock option covering 1,388,274 shares of common stock, expiring on December 4, 2035. The exercise price is $17.80 per share, or $8.18 per share if the option is exercised after a defined “Retention Period” that runs from December 5, 2025 through the earlier of December 5, 2027 or a qualifying change in control during continuous service. One quarter of the option vests on July 1, 2026, with the rest vesting in equal monthly installments over three years, subject to continued service. Share counts reflect a 1-for-20 reverse stock split completed on September 18, 2025.
Vor Biopharma Inc. filed its Q3 2025 10‑Q, highlighting a pivot to autoimmune diseases centered on telitacicept and significant non‑cash items that dominated results. The company reported a net loss of $812.7 million for the quarter and $2,418.8 million for the nine months, largely driven by a $790.5 million quarterly and $2,090.4 million year‑to‑date change in the fair value of liability‑classified warrants.
Operating expenses were $28.1 million in Q3, including $14.1 million for R&D and $14.0 million for G&A. Year‑to‑date, R&D includes a $222.6 million charge for the telitacicept license (cash $45.0 million plus a warrant initially valued at $177.4 million) and $29.7 million of restructuring costs tied to the wind‑down of prior programs and a lease termination.
Cash, cash equivalents and marketable securities were $170.5 million as of September 30, 2025. Subsequent financings added $49.8 million via an October at‑the‑market sale and approximately $93.7 million from a November underwritten offering, with an additional $14.1 million expected from the overallotment. Management projects liquidity to fund operations into the second quarter of 2027.
Vor Biopharma Inc. announced a public equity offering of 10,000,000 shares at $10.00 per share. The Company expects net proceeds of approximately $93.7 million, or $107.8 million if underwriters exercise a 30-day option to purchase up to 1,500,000 additional shares, with closing expected on November 12, 2025, subject to customary conditions.
Vor plans to use proceeds to advance telitacicept clinical development, including initiation of a Phase 3 trial for primary Sjögren’s Disease, along with manufacturing, pre-commercialization, working capital and general corporate purposes. Including $49.8 million of net proceeds from recent ATM sales, the Company believes its cash resources will fund operations into the second quarter of 2027. Shares outstanding were 9,026,922 as of September 30, 2025.
Vor Biopharma (VOR) launched a primary offering of 10,000,000 shares of common stock at $10.00 per share, a follow-on under its shelf registration. The deal includes a 30‑day option for underwriters to purchase up to 1,500,000 additional shares. The pricing table lists a public offering price of $10.00, underwriting discounts of $0.60 per share, and proceeds to the company of $9.40 per share before expenses. Vor estimates net proceeds of approximately $93.7 million after fees and expenses.
The company plans to use proceeds to advance telitacicept, including a Phase 3 trial in primary Sjögren’s disease, plus manufacturing, pre‑commercialization, working capital and general corporate purposes. Vor noted it is an emerging growth and smaller reporting company and completed a 1‑for‑20 reverse stock split on September 18, 2025. The company agreed to a 60‑day lock‑up (90 days for directors, officers and certain stockholders) and to pause sales under its ATM program for 30 days unless the underwriters’ option is exercised in full.
Vor Biopharma (VOR) launched a primary offering of $100,000,000 of common stock, with underwriters granted a 30‑day option to purchase up to an additional $15,000,000 of shares. The company’s stock trades on Nasdaq as “VOR.” On November 7, 2025, the last reported sale price was $18.70 per share. All share figures reflect the 1‑for‑20 reverse split effected on September 18, 2025.
Vor plans to use net proceeds to advance telitacicept, including a Phase 3 trial in primary Sjögren’s disease, manufacturing and pre‑commercialization activities, and for working capital and general corporate purposes. The company and certain insiders agreed to lock‑ups (company 60 days; directors, officers and certain stockholders 90 days). Vor also agreed not to sell under its ATM program for 30 days after this offering unless the underwriters’ option is exercised in full.
Shares outstanding were 6,282,297 as of June 30, 2025. This figure provides a baseline and is separate from the amount being offered.
Vor Biopharma Inc. filed Amendment No. 1 to its Form S-3, covering the resale by selling stockholders of up to 50,999,999 shares of common stock after effectiveness. The amendment adds Rule 473(b) language for automatic effectiveness 20 days after filing.
The shares consist of up to 16,000,000 issuable upon exercise of the RemeGen Warrant and up to 34,999,999 issuable upon exercise of PIPE Warrants; all figures reflect the 1-for-20 reverse stock split effected on September 18, 2025. The company will not receive proceeds from stockholder resales; it would receive cash only upon warrant exercises at $0.002 per share, totaling approximately $102,000 if fully exercised for cash. Examples of registered resale amounts include RemeGen Co., Ltd. 16,000,000 and RA Capital Healthcare Fund, L.P. 10,000,000. Shares outstanding were 6,853,907 as of September 18, 2025.